Systemic rituximab for the treatment of the indolent forms of primary cutaneous B-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry - 10/10/20
Doi : 10.1016/j.jaad.2020.07.028
Cristina Muniesa, MD, PhD a, b, Eva Domingo-Domenech, MD c, Rosa Fornons-Servent, MD a, Yeray Peñate, MD, PhD d, M. Teresa Estrach, MD, PhD e, M. Dolores Ramón, MD f, Susana Medina, MD g, Ángeles Flórez, MD, PhD h, Pablo L. Ortiz-Romero, MD, PhD i, M. Prado Sánchez-Caminero, MD j, Ignacio Torres-Navarro, MD k, Elvira Acebo, MD, PhD l, Ignacio Yanguas, MD m, Ricardo Fernández-de-Misa, MD, PhD n, Mar Blanes, MD, PhD o, Ana Zayas, MD p, Miguel A. Descalzo, MSc, PhD q, Ignacio Garcia-Doval, MD, PhD q, Octavio Servitje, MD, PhD a, ⁎ 
a Department of Dermatology, Hospital Universitari de Bellvitge, Universitat de Barcelona, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain
b Department of Dermatology, Hospital de Viladecans, Viladecans, Barcelona, Spain
c Derpartment of Hematology, Institut Català d'Oncologia, Hospital Duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de LLobregat, Barcelona, Spain
d Department of Dermatology, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Las Palmas, Spain
e Department of Dermatology, Hospital Clínic, Universitat de Barcelona, Instituto de Investigaciones Biomédicas August Pi i Sunyer, Barcelona, Spain
f Department of Dermatology, Hospital Clínico Universitario de Valencia, Valencia, Spain
g Department of Dermatology, Hospital de Alcalá de Henares, Madrid, Spain
h Department of Dermatology, Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain
i Department of Dermatology, Hospital 12 de Octubre, Institute I+12 Research Institute, Universidad Complutense, Madrid, Spain
j Department of Dermatology, Hospital General Universitario, Ciudad Real, Spain
k Department of Dermatology, Hospital Universitario La Fe, Valencia, Spain
l Department of Dermatology, Hospital Universitario de Cruces, Barakaldo, Bizkaia, Spain
m Department of Dermatology, Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
n Department of Dermatology, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain
o Department of Dermatology, Hospital General Universitario, Alicante, Spain
p Department of Dermatology, Hospital Universitario Dr Peset, Valencia, Spain
q Research Unit, Fundación Piel Sana Academia Española de Dermatología, Madrid, Spain
∗Correspondence to: Octavio Servitje, MD, PhD, Department of Dermatology, Hospital Universitari de Bellvitge, IDIBELL. Barcelona University, c/Feixa LLarga s/n, 08907-L'Hospitalet de Llobregat, Barcelona, SpainDepartment of DermatologyHospital Universitari de BellvitgeIDIBELL. Barcelona Universityc/Feixa LLarga s/n, 08907-L'Hospitalet de LlobregatBarcelonaSpain
| Drs Muniesa and Domingo-Domenech contributed equally to this article. |
|
| Funding sources: The Spanish Primary Cutaneous Lymphoma Registry (RELCP) is promoted by the Fundación Piel Sana Academia Española de Dermatología y Venereología, which received an unrestricted grant support from Kyowa Kirin Limited, United Kingdom. Collaborating pharmaceutical companies were not involved in the design and conducting of the study; collection, management, analysis and interpretation of data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. |
|
| Conflicts of interest: None disclosed. |
|
| Part of this work was presented as a poster at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Task Force Clinical Meeting, Athens, Greece, September 26-29, 2019. |
|
| IRB approval status: IRB Hospital Universitari de Bellvitge, November 8, 2018 (EPAA048/18). |
|
| Reprints not available from the author(s). |
© 2020
Publié par Elsevier Masson SAS.
Vol 83 - N° 5
P. 1535-1538 - novembre 2020 Retour au numéro
Article précédent
- The role of dupilumab in the management of idiopathic chronic eczematous eruption of aging
- Neda Shahriari, Bruce Strober, Mona Shahriari
- Risk assessment of outpatient dermatology practice in the setting of the COVID-19 pandemic
- Pedram Gerami, Walter Liszewski
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?